知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

115 records (took 0.063 seconds)

    Treatment and diagnosis of cancer
    2.
    发明授权
    Treatment and diagnosis of cancer 有权
    癌症的治疗和诊断

    公开(公告)号：US08951737B2

    公开(公告)日：2015-02-10

    申请号：US11939422

    申请日：2007-11-13

    Applicant: Neil H. Bander

    Inventor： Neil H. Bander

    IPC: G01N33/53 ,  G01N33/574 ,  A61K39/395 ,  A61K47/48 ,  B82Y5/00 ,  C07K16/30 ,  A61K39/00

    CPC classification number: A61K47/48638 ,  A61K47/6869 ,  A61K47/6899 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3069 ,  C07K2317/77 ,  G01N33/57434 ,  G01N2333/705

    Abstract: Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

    Abstract translation: 使用抗体或其结合部分，探针，配体或其他生物制剂，其识别前列腺特异性膜抗原（PSMA）的细胞外结构域或与PSMA结合并内化。 这些生物制剂可被标记并用于检测癌组织，特别是表达PSMA细胞外结构域的靠近或含有血管内皮细胞的癌组织。 标记的生物制剂也可用于检测正常，良性增生和癌性前列腺上皮细胞或其部分。 它们也可以单独使用或与有效消融或杀死这种细胞的物质结合，如用于前列腺癌或其他癌症的治疗。 还公开了四种杂交瘤细胞系，其各自产生识别正常，良性增生性和癌性前列腺上皮细胞或其部分的PSMA的细胞外结构域的单克隆抗体。

    Use of specifically engineered enzymes to enhance the efficacy of prodrugs
    4.
    发明授权
    Use of specifically engineered enzymes to enhance the efficacy of prodrugs 有权
    使用特异性工程化的酶来增强前药的功效

    公开(公告)号：US07858745B2

    公开(公告)日：2010-12-28

    申请号：US11760399

    申请日：2007-06-08

    Applicant: Arnon Lavie ,  Manfred Konrad ,  Farhad Ravandi

    Inventor： Arnon Lavie ,  Manfred Konrad ,  Farhad Ravandi

    IPC: C07K14/00 ,  C12N15/00

    CPC classification number: B82Y5/00 ,  A61K47/6815 ,  A61K47/6899 ,  C07K16/2803 ,  C07K2319/30 ,  C12N9/1205

    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.

    Abstract translation: 本发明提供了通过特异性工程化的酶提高前药的效率的方法，所述酶具有增强的对癌症化疗中使用的核苷类似物的活性，并将酶递送到患者中的特定靶细胞。 本发明还提供具有这种增强活性的修饰的脱氧胞苷激酶（dCK）突变体。 此外，本发明提供可以在体内或体外特异性递送至白血病胚胎细胞的抗体缀合的酶。

    Treatment and diagnosis of cancer
    8.
    发明申请
    Treatment and diagnosis of cancer 审中-公开

    公开(公告)号：US20060275212A1

    公开(公告)日：2006-12-07

    申请号：US11481344

    申请日：2006-07-05

    Applicant: Neil Bander

    Inventor： Neil Bander

    IPC: A61K51/00 ,  G01N33/574 ,  A61K39/395

    CPC classification number: A61K47/6869 ,  A61K47/6899 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3069 ,  C07K2317/77 ,  G01N33/57434 ,  G01N2333/705

    Abstract: The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of prostate specific membrane antigen. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cell lines, each of which produces a monoclonal antibody recognizing extracellular domains of prostate specific membrane antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

    Multi-triggered self-immolative dendritic compounds
    9.
    发明申请
    Multi-triggered self-immolative dendritic compounds 审中-公开
    多触发自褪色树枝状化合物

    公开(公告)号：US20060269480A1

    公开(公告)日：2006-11-30

    申请号：US11443107

    申请日：2006-05-31

    Applicant: Roey Amir ,  Doron Shabat

    Inventor： Roey Amir ,  Doron Shabat

    IPC: A61K51/00 ,  A61K31/787 ,  C08G69/00

    CPC classification number: A61K31/787 ,  A61K47/555 ,  A61K47/67 ,  A61K47/6899 ,  B82Y5/00

    Abstract: Novel self-immolative dendritic compounds which have a plurality of cleavable trigger units and hence can release a chemical moiety at their focal point upon a multi-triggering mechanism are disclosed. The novel self-immolative dendritic compounds are gated by a molecular logic gate, being either an AND or OR logic gate and hence can be beneficially used in a variety of biological, chemical and physical applications. Processes of preparing, compositions containing and methods utilizing the novel dendritic compounds are further disclosed.

    Abstract translation: 公开了具有多个可裂解触发单元并因此可以在多重触发机制下在其焦点释放化学部分的新型自褪色树枝状化合物。 新型自褪色树枝状化合物由分子逻辑门选通，或者是或逻辑门，因此可以有益地用于各种生物，化学和物理应用。 进一步公开了制备方法，含有组合物和利用新型树枝状化合物的方法。

Patent Agency Ranking